mProX™ Human PAK5 Stable Cell Line

Sub Cat	Product Name	Target Protein Species	Host Cell Type	Assay Types	Inquiry	Datasheet
S01YF-1222-KX419	Magic™ Human PAK5(PAK7) in Vitro Assay	Human		Kinase Assay

Product Information

Target Family

Kinases/Enzyme

Target Protein Species

Human

Host Cell Type

HEK293;CHO-K1;HeLa;SiHa

Target Classification

Kinase Cell Lines

Target Research Area

Cancer Research

Related Diseases

Breast Large Cell Neuroendocrine Carcinoma; Trichorhinophalangeal Syndrome, Type I

Gene ID

Human:57144

UniProt ID

Human:Q9P286

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

PAK5 was found within genomic regions associated with resistance, suggesting its potential role in immune system and inflammatory response functions. In cancer research, PAK5 was shown to be involved in inhibiting the progression of cervical cancer. HPV E7 was found to promote cervical cancer progression by modulating the m6A modification of PAK5, suggesting PAK5 as a potential therapeutic target for cervical cancer. PAK5 was also found to be involved in the regulation of microRNA biogenesis through Drosha phosphorylation. This mechanism of regulation may have implications in cancer and other diseases. In the context of spinal cord injury, inhibiting the mitochondrial docking protein Snph, which is involved in mitochondrial transport, can enhance axonal mitochondrial transport and improve the regeneration of axons. PAK5 may play a role in this process by enhancing mitochondrial transport.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human PAK5 Stable Cell Line (S01YF-1023-PY44). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Taylor Williams (Verified Customer)

How does PAK5 influence neuron survival and regeneration? Sep 22 2023

chat Patrick Liam (Creative Biolabs Scientific Support)

PAK5 is involved in an energetic AKT-PAK5 axis that facilitates neuron survival and regeneration after injury and ischemia by maintaining axon energy supply. Sep 22 2023

chat Skyler Miller (Verified Customer)

What role does PAK5 play in breast cancer? Jan 26 2021

chat Patrick Liam (Creative Biolabs Scientific Support)

PAK5-mediated AIF phosphorylation inhibits its nuclear translocation, promoting breast cancer tumorigenesis. Jan 26 2021

Published Data

Fig.1 In vitro, PAK5 stimulates the migration and invasion of CC cells.

The migration and invasion abilities were assessed through Transwell assays in HeLa and SiHa cells, with PAK5 overexpression and knockdown, respectively. A scale bar of 100 μm was employed for the figures denoted as 'g' and 'h'. The data were presented as mean ± SD based on three independent experiments. Significance levels were indicated as *, P < 0.05; **, P < 0.01; ***, P < 0.001. The Cell Counting Kit-8 (CCK-8) was used for cell counting, and siRNA control (siCtrl) and siRNA targeting PAK5 (siPAK5) were utilized.

Ref: Huo, Fu-Chun, et al. "PAK5 promotes the migration and invasion of cervical cancer cells by phosphorylating SATB1." Cell Death & Differentiation 26.6 (2019): 994-1006.

Pubmed: 30082769

DOI: 10.1038/s41418-018-0178-4

Research Highlights

Xing, Yao et al. "PAK5-mediated AIF phosphorylation inhibits its nuclear translocation and promotes breast cancer tumorigenesis." International journal of biological sciences vol. 17,5 1315-1327. 27 Mar. 2021.
Despite its association with various cancer types, the precise role of PAK5 in breast cancer has remained uncertain. This investigation uncovers a pivotal function for PAK5 in thwarting apoptosis by impeding AIF's migration into the nucleus. In breast cancer cells, PAK5 hampers AIF release from mitochondria by modulating membrane properties, heightening the membrane potential, and phosphorylating AIF at Thr281 to hinder AIF/importin α3 complex formation, thereby curtailing AIF nuclear translocation. Functionally, this PAK5-mediated AIF phosphorylation fosters breast cancer cell proliferation and in vivo tumor growth. Remarkably, higher PAK5 and AIF levels in breast cancer correspond with unfavorable patient outcomes, emphasizing the therapeutic potential of targeting the PAK5-AIF pathway in breast cancer treatment.
Xing, Yao et al. "PAK5-mediated AIF phosphorylation inhibits its nuclear translocation and promotes breast cancer tumorigenesis." International journal of biological sciences vol. 17,5 1315-1327. 27 Mar. 2021.
Pubmed: 33867848 DOI: 10.7150/ijbs.58102

L Martin, Heather. et al. "Affimer-mediated locking of p21-activated kinase 5 in an intermediate activation state results in kinase inhibition." Cell reports, 2023.
Kinases are significant targets for therapeutic purposes and their inhibitors are categorized based on their mechanism of action, ranging from blocking ATP binding to covalent inhibition. A new method of inhibition is proposed by utilizing an Affimer, which binds to the P+1 pocket of p21-activated kinase 5 (PAK5) and captures it in an intermediate state of activation. PAK5 was identified through a non-hypothesis-driven high-content imaging RNAi screen in urothelial cancer cells. Its suppression led to reduced cell number, G1/S arrest, and enlarged cells, underscoring its role in the survival and proliferation of the urothelial cancer cell line. Affimer reagents were used to identify the mode of inhibition, and PAK5-Af17 was found to mimic the effects of siRNA. Co-crystallization revealed that PAK5-Af17 binds to the P+1 pocket, causing the kinase to be partially activated. This novel mechanism of inhibition highlights the potential for a new class of kinase inhibitors.
L Martin, Heather. et al. "Affimer-mediated locking of p21-activated kinase 5 in an intermediate activation state results in kinase inhibition." Cell reports, 2023.
Pubmed: 37776520 DOI: 10.1016/j.celrep.2023.113184